Cargando…
On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer
We addressed a significant unknown feature of circulating tumor DNA (ctDNA), i.e., how ctDNA levels change during chemotherapy, by serially monitoring ctDNA in patients with colorectal cancer during the 48-h application of FOLFOX. Surprisingly, we did not observe a spike in ctDNA as a sign of a resp...
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666126/ https://www.ncbi.nlm.nih.gov/pubmed/33299124 http://dx.doi.org/10.1038/s41698-020-00134-3 |
| _version_ | 1783610072309432320 |
|---|---|
| author | Moser, Tina Waldispuehl-Geigl, Julie Belic, Jelena Weber, Sabrina Zhou, Qing Hasenleithner, Samantha O. Graf, Ricarda Terzic, Jasmin Alia Posch, Florian Sill, Heinz Lax, Sigurd Kashofer, Karl Hoefler, Gerald Schoellnast, Helmut Heitzer, Ellen Geigl, Jochen B. Bauernhofer, Thomas Speicher, Michael R. |
| author_facet | Moser, Tina Waldispuehl-Geigl, Julie Belic, Jelena Weber, Sabrina Zhou, Qing Hasenleithner, Samantha O. Graf, Ricarda Terzic, Jasmin Alia Posch, Florian Sill, Heinz Lax, Sigurd Kashofer, Karl Hoefler, Gerald Schoellnast, Helmut Heitzer, Ellen Geigl, Jochen B. Bauernhofer, Thomas Speicher, Michael R. |
| author_sort | Moser, Tina |
| collection | PubMed |
| description | We addressed a significant unknown feature of circulating tumor DNA (ctDNA), i.e., how ctDNA levels change during chemotherapy, by serially monitoring ctDNA in patients with colorectal cancer during the 48-h application of FOLFOX. Surprisingly, we did not observe a spike in ctDNA as a sign of a responsive tumor, but instead ctDNA levels initially decreased and remained low in patients with stable disease or partial response. Our observations reveal further insights into cell destruction during chemotherapy with important implications for the management of patients. |
| format | Online Article Text |
| id | pubmed-7666126 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76661262020-11-16 On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer Moser, Tina Waldispuehl-Geigl, Julie Belic, Jelena Weber, Sabrina Zhou, Qing Hasenleithner, Samantha O. Graf, Ricarda Terzic, Jasmin Alia Posch, Florian Sill, Heinz Lax, Sigurd Kashofer, Karl Hoefler, Gerald Schoellnast, Helmut Heitzer, Ellen Geigl, Jochen B. Bauernhofer, Thomas Speicher, Michael R. NPJ Precis Oncol Brief Communication We addressed a significant unknown feature of circulating tumor DNA (ctDNA), i.e., how ctDNA levels change during chemotherapy, by serially monitoring ctDNA in patients with colorectal cancer during the 48-h application of FOLFOX. Surprisingly, we did not observe a spike in ctDNA as a sign of a responsive tumor, but instead ctDNA levels initially decreased and remained low in patients with stable disease or partial response. Our observations reveal further insights into cell destruction during chemotherapy with important implications for the management of patients. Nature Publishing Group UK 2020-11-13 /pmc/articles/PMC7666126/ /pubmed/33299124 http://dx.doi.org/10.1038/s41698-020-00134-3 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Brief Communication Moser, Tina Waldispuehl-Geigl, Julie Belic, Jelena Weber, Sabrina Zhou, Qing Hasenleithner, Samantha O. Graf, Ricarda Terzic, Jasmin Alia Posch, Florian Sill, Heinz Lax, Sigurd Kashofer, Karl Hoefler, Gerald Schoellnast, Helmut Heitzer, Ellen Geigl, Jochen B. Bauernhofer, Thomas Speicher, Michael R. On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer |
| title | On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer |
| title_full | On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer |
| title_fullStr | On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer |
| title_full_unstemmed | On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer |
| title_short | On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer |
| title_sort | on-treatment measurements of circulating tumor dna during folfox therapy in patients with colorectal cancer |
| topic | Brief Communication |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666126/ https://www.ncbi.nlm.nih.gov/pubmed/33299124 http://dx.doi.org/10.1038/s41698-020-00134-3 |
| work_keys_str_mv | AT mosertina ontreatmentmeasurementsofcirculatingtumordnaduringfolfoxtherapyinpatientswithcolorectalcancer AT waldispuehlgeigljulie ontreatmentmeasurementsofcirculatingtumordnaduringfolfoxtherapyinpatientswithcolorectalcancer AT belicjelena ontreatmentmeasurementsofcirculatingtumordnaduringfolfoxtherapyinpatientswithcolorectalcancer AT webersabrina ontreatmentmeasurementsofcirculatingtumordnaduringfolfoxtherapyinpatientswithcolorectalcancer AT zhouqing ontreatmentmeasurementsofcirculatingtumordnaduringfolfoxtherapyinpatientswithcolorectalcancer AT hasenleithnersamanthao ontreatmentmeasurementsofcirculatingtumordnaduringfolfoxtherapyinpatientswithcolorectalcancer AT grafricarda ontreatmentmeasurementsofcirculatingtumordnaduringfolfoxtherapyinpatientswithcolorectalcancer AT terzicjasminalia ontreatmentmeasurementsofcirculatingtumordnaduringfolfoxtherapyinpatientswithcolorectalcancer AT poschflorian ontreatmentmeasurementsofcirculatingtumordnaduringfolfoxtherapyinpatientswithcolorectalcancer AT sillheinz ontreatmentmeasurementsofcirculatingtumordnaduringfolfoxtherapyinpatientswithcolorectalcancer AT laxsigurd ontreatmentmeasurementsofcirculatingtumordnaduringfolfoxtherapyinpatientswithcolorectalcancer AT kashoferkarl ontreatmentmeasurementsofcirculatingtumordnaduringfolfoxtherapyinpatientswithcolorectalcancer AT hoeflergerald ontreatmentmeasurementsofcirculatingtumordnaduringfolfoxtherapyinpatientswithcolorectalcancer AT schoellnasthelmut ontreatmentmeasurementsofcirculatingtumordnaduringfolfoxtherapyinpatientswithcolorectalcancer AT heitzerellen ontreatmentmeasurementsofcirculatingtumordnaduringfolfoxtherapyinpatientswithcolorectalcancer AT geigljochenb ontreatmentmeasurementsofcirculatingtumordnaduringfolfoxtherapyinpatientswithcolorectalcancer AT bauernhoferthomas ontreatmentmeasurementsofcirculatingtumordnaduringfolfoxtherapyinpatientswithcolorectalcancer AT speichermichaelr ontreatmentmeasurementsofcirculatingtumordnaduringfolfoxtherapyinpatientswithcolorectalcancer |